<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848093</url>
  </required_header>
  <id_info>
    <org_study_id>160/08</org_study_id>
    <nct_id>NCT01848093</nct_id>
  </id_info>
  <brief_title>Mucin Concentration in Sputum From COPD Patients During a Pulmonary Exacerbation</brief_title>
  <acronym>mucinCOPDex</acronym>
  <official_title>Molekularbiologische Eigenschaften Des Sputums w√§hrend Einer Pulmonalen COPD Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      chronic obstructive pulmonary disease (COPD) is typically associated with mucus&#xD;
      hypersecretion in the airways. In health, mucin is the major macromolecular component and is&#xD;
      responsible for the protective and clearance properties of the mucus gel. In a recent study&#xD;
      the investigators found that mucins are decreased and unstable in the sputum of adult cystic&#xD;
      fibrosis (CF) patients.&#xD;
&#xD;
      In this study the investigators want to investigate the differences on the mucin quantity and&#xD;
      quality of airway secretions during pulmonary exacerbation of patients with COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that during an exacerbation the mucin amount is increasing.&#xD;
&#xD;
      The aim of this study is to evaluate the molecular (mucins) and structure properties&#xD;
      (mucin-stability) of the airway secretions in COPD related to the severity of the disease.&#xD;
&#xD;
      We characterize sputum composition of patients with pulmonary exacerbations. Using gel&#xD;
      electrophoresis, with specific antibodies we will analyze MUC5AC and MUC5B mucins.&#xD;
&#xD;
      The significance of these studies is that they will give us novel information about the&#xD;
      pathogenesis of chronic inflammatory airway diseases, provide tools for assessing the&#xD;
      progression of lung disease, and most critically, will identify novel opportunities and&#xD;
      targets for therapeutic intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mucin concentration</measure>
    <time_frame>2 month</time_frame>
    <description>analyzing mucin concentration by western</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mucin stability</measure>
    <time_frame>2 month</time_frame>
    <description>analyzing mucin stability at 37C over 24 hours</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>COPD exacerbation</arm_group_label>
    <description>COPD Stadium 2 and 3 during pulmonary exacerbation&#xD;
sputum collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sputum collection</intervention_name>
    <description>collecting of spontaneous sputum from the patient</description>
    <arm_group_label>COPD exacerbation</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      sputum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients Stadium 2-3 during pulmonary exacerbation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  forced expiratory volume at one second (FEV1) &lt; 80%&#xD;
&#xD;
          -  sputum production&#xD;
&#xD;
          -  clinical likely hood of exacerbation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  FEV1 &gt; 80% or &lt; 30%&#xD;
&#xD;
          -  increased systemic inflammation&#xD;
&#xD;
          -  susceptibility of pneumonia&#xD;
&#xD;
          -  need for antibiotic treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Henke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Marburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>pulmonary department, University Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions. Am J Respir Cell Mol Biol. 2004 Jul;31(1):86-91. Epub 2004 Feb 26.</citation>
    <PMID>14988081</PMID>
  </reference>
  <reference>
    <citation>Henke MO, John G, Rheineck C, Chillappagari S, Naehrlich L, Rubin BK. Serine proteases degrade airway mucins in cystic fibrosis. Infect Immun. 2011 Aug;79(8):3438-44. doi: 10.1128/IAI.01252-10. Epub 2011 Jun 6.</citation>
    <PMID>21646446</PMID>
  </reference>
  <reference>
    <citation>Henke MO, John G, Germann M, Lindemann H, Rubin BK. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am J Respir Crit Care Med. 2007 Apr 15;175(8):816-21. Epub 2007 Jan 25.</citation>
    <PMID>17255563</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>May 2, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung</keyword>
  <keyword>airway</keyword>
  <keyword>pulmonary exacerbation</keyword>
  <keyword>mucus</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

